



8th August 2023

Respiri Successfully Raises A\$3M Through its Share Purchase Plan and Subsequent Shortfall Placement

Respiri Limited (ASX:RSH; OTCQB:RSHUF) ("Respiri" or the "Company"), an eHealth SaaS Company supporting respiratory remote patient monitoring, is pleased to announce that the Company has successfully completed the previously announced A\$3M Share Purchase Plan ("SPP") (refer SPP Offer Booklet announced to the ASX on 30 June 2023) by raising A\$2,385,420 through the Offer and \$614,580 in a Shortfall Placement, which has been strongly supported. The Company welcomes the continued support of its existing shareholders and incoming investors.

The proceeds from the combined capital raise will be primarily utilised for the upfront payment to acquire 100% of Access Managed Services LLC (Access), followed by working capital for US commercialisation acceleration and the subsequent 3-month tranche of the Access acquisition. Both the Access and Respiri teams have been working on plans to achieve benefits from their respective complementary commercial competencies. All Access key personnel have chosen to remain as members of the newly merged organisation, a further testament to the significant RPM opportunities that exist in the USA for Respiri/Access. The teams continue working on significant RPM business opportunities founded on wheezo® device differentiation and the world-class RPM services and Remotli platform provided by Access, which the Company hopes to announce over the coming months.

Cost rationalization was realized in both the March and June quarters which will be complemented by the renewed balance sheet and synergies from the acquisition that will support revenue generation, driving an accelerated timeline to operational breakeven of Respiri's USA operations in mid CY2024.

Marjan, CEO of Respiri, said "The opportunities the USA provides in Remote Patient Monitoring (RPM) are very attractive. Much has been achieved in 18 months; we were the first Australian MedTech Company to generate revenue from US Healthcare Organisation successfully claiming RPM CPT reimbursement codes when providing wheezo®, an FDA approved medical device, to their patients. With the acquisition of Access, the Company is the first to deliver an end-to-end RPM solution across all major disease states, supporting our HCO clients to provide better care to all their eligible patients, improve health outcomes and significantly reduce costs".

Knowing the significance of what the Access and Respiri teams are currently collaborating on provides a great sense of business optimism as Respiri continues to break new commercial ground as an Australian MedTech company successfully taking on the USA market and building a business that aims to be breakeven by mid-2024. Our shareholder support on the SPP represents a significant endorsement of our US strategy underpinned by the acquisition of Access."

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.



About Respiri Limited

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is an international e-Health SaaS company supporting respiratory health management focusing primarily on supporting the US remote patient monitoring market. Its world-first technology detects wheeze, a typical symptom of Asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respiri created technology optimises how patients in partnership with their physicians manage chronic respiratory conditions. These solutions can help transform the way physicians interact with respiratory patients while they are away from the clinic. wheezo®, is an FDA cleared Class II Medical Device, the respiri™ app (patient-user-interface) and the secure health portal can help different health organisations and providers connect with patients to improve collaboration and help improve respiratory condition management. In the USA, wheezo® can be integrated into Remote Patient Monitoring (RPM) programs and qualifies for RPM Current Procedural Terminology (CPT) reimbursement.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world with respiratory disorders and dramatically reduce hospital admissions and the economic burden of Asthma and COPD. Respiri Limited's operations are based in Melbourne, Australia with offices in New York City, USA.

For additional information about Respiri Limited please visit our corporate website www.respiri.co/au

About wheezo®

Developed in Australia, with the support of an international panel of leading respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the intuitive mobile application engages patients to log symptoms and triggers to build a personal profile to share data with healthcare providers so patients and physicians can have more informed discussions in relation to symptoms. The platform has been designed to extend care beyond the clinic which may lead to better health outcomes and improved quality of life for patients.

For information about our product offering in the US including wheezo® please visit www.respiri.co/us

wheezo® is a registered trademark of Respiri Limited.

About Access Telehealth

Access Telehealth is a digital health company dedicated to delivering innovative connected care solutions for management of people living with chronic disease. The Remotli platform uniquely simplifies remote care delivery with patient engagement and productivity driven dashboard tools to support effective patient care and compliance. Automated care-time tracking, and reimbursement reports makes it easy to boost revenue to support vital chronic disease management programs including Remote Physiologic Monitoring, Remote Therapeutic Monitoring, Transitional Care, Chronic Care Management, Telemedicine and more. Focusing on Remote Physiologic Monitoring and virtual care initiatives, the Access Telehealth clinical team delivers patient-centric remote monitoring services to support disease specific chronic care programs for health systems, payors, and providers, to enhance care delivery. www.accessrpm.com

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.